Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced today that
the United States Patent Office issued to Sirtris the first patent
covering a broad class of compounds that activate the enzyme SIRT1.
Several Sirtris compounds—or new chemical
entities (NCEs)—from this class lower glucose
and improve insulin sensitivity in preclinical models of Type 2
Diabetes. The patent covers the first NCE that Sirtris plans to take
into a human clinical safety trial in the first half of 2008.
“Just five months ago in the publication Nature,
we reported the identification of new chemical entities that lower
glucose and improve insulin sensitivity in preclinical models that the
FDA—in recent draft guidance—recommended
for the development of Type 2 Diabetes drugs,”
says Christoph Westphal, M.D., Ph.D., Chief Executive Officer and Vice
Chair of Sirtris Pharmaceuticals. “We are very
pleased to have the first patent covering a class of compounds that have
the potential to be a frontline therapy for Type 2 Diabetes.”
“Sirtris has a strong intellectual property
program with over 180 patent applications for broad coverage of sirtuin
activators, including composition of matter, formulations, and methods
of treatment claims,” says Karl Normington,
Ph.D., Senior Director of Intellectual Property at Sirtris
Pharmaceuticals. “This is the first patent
issued by the U.S. Patent Office covering a class of compounds known to
activate SIRT1.”
In 2006, consecutive papers in the journals Cell and Nature
by Sirtris scientists and Sirtris co-founder David Sinclair, Ph.D. of
Harvard Medical School, showed that resveratrol, a SIRT1 activator found
in red wine, could reduce the impact of a high fat diet, increase
stamina two fold and significantly extend lifespan of mice. However, it
is estimated that a person would need to drink roughly 1000 bottles of
red wine per day to obtain the equivalent dose of resveratrol used in
these studies. Sirtris has developed SIRT1 activating molecules that are
chemically distinct from, and up to 1000 times more potent in in-vitro
studies than resveratrol.
The sirtuins are a family of seven enzymes that help regulate the body's
natural defense against disease. In preclinical research, members of the
sirtuin family have been shown to have protective effects against
various diseases such as Type 2 Diabetes, metabolic diseases,
cardiovascular disease, neurodegeneration, inflammation and cancer.
Future sirtuin therapeutics may have the potential to treat diseases of
aging in a new way.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that the
Company believes control the aging process. The Company's headquarters
are in Cambridge, Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of sirtuins and SIRT1 activators, including novel chemical
entities and SRT501, for diseases of aging, such as Type 2 Diabetes; the
progress and potential results of preclinical and clinical studies of
SIRT1 activators; the success of SIRT1 activators as therapies for
diseases, such as Type 2 Diabetes; and the potential of sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of Sirtris
Pharmaceuticals involve significant risks, uncertainties and
assumptions, including risks related to the lack of results that would
provide a basis for predicting whether any of the Company's product
candidates will be safe or effective, or receive regulatory approval,
the possibility that results of pre-clinical studies are not necessarily
predictive of clinical trial results, the Company's potential inability
to initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential inability of
the Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission. Actual
results may differ materially from those Sirtris Pharmaceuticals
contemplated by these forward-looking statements. Sirtris
Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date of this release.